Why Mustang Bio's Stock Is Trading Higher Today
Portfolio Pulse from Vandana Singh
Mustang Bio Inc (NASDAQ:MBIO) announced positive final data from the follicular lymphoma cohort of the Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T-cell therapy. The treatment demonstrated high overall response and complete response rates, with a favorable safety profile. MBIO shares are up 9.44% at $8.00.
June 16, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mustang Bio's MB-106 CAR T-cell therapy showed positive results in a Phase 1/2 clinical trial, leading to a 9.44% increase in MBIO shares.
The positive results from the Phase 1/2 clinical trial of MB-106 demonstrate the potential of the therapy in treating follicular lymphoma. This news directly impacts Mustang Bio's stock price, as it indicates progress in the development of their product, leading to a 9.44% increase in MBIO shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100